April 25th 2024
Rinvoq (upadacitinib) shows efficacy in both itch resolution and skin clearance in the treatment of patients with atopic dermatitis.
Boehringer Ingelheim Delivers Promising Results in Phase II Chronic Kidney Disease Trial
November 6th 2023BI 690517 is a novel, potent, highly selective aldosterone synthase inhibitor that reduces the progression of kidney damage and lowers the risk of cardiovascular events in patients with chronic kidney disease.
FDA Approves Keytruda Plus Chemotherapy for Biliary Tract Cancer
November 1st 2023The approval of pembrolizumab (Keytruda; Merck) combined with gemcitabine and cisplatin for the treatment locally advanced unresectable or metastatic biliary tract cancer is the sixth sixth indication for the anti-PD-1 therapy for gastrointestinal cancers.
Bridging Care Delivery with Clinical Research
July 17th 2023In this Q&A, Craig Serra, head of commercial solutions and partnerships within the clinical research business unit at Flatiron Health (affiliate of the Roche Group), shares his perspective on clinical research, the role of data, and Flatiron Health’s efforts to that end.
From Physician to Pharma: Gynecologic Oncologist Enters Clinical Trials Space
July 13th 2023In an interview with Applied Clinical Trials' sister publication, Pharmaceutical Executive, Elizabeth (Beth) Garner, chief scientific officer for Ferring Pharmaceuticals, discusses what it was like transitioning from working as a gynecologic oncologist and seeing patients to working in pharma, specifically clinical trials.
Charting the Course of Gene Therapy: A Conversation with Sangamo Therapeutics
June 12th 2023Nathalie Dubois-Stringfellow, Sangamo’s chief development officer discusses the company's diverse clinical programs, strategic collaborations, including a partnership with Pfizer, and the crucial role of patient safety.
Breaking New Ground in Cardiovascular Health: Innovative Approaches in Clinical Trial Design
May 22nd 2023In this Q&A, John Kastelein, MD, founder and chief scientific officer, NewAmsterdam Pharma, discusses the challenges and opportunities within the cardiovascular field, exploring the current landscape for lipid-lowering therapies and the unique potential advantages of CETP inhibitors.
The OSCAR Study: Unlocking the Power of Real-World Evidence in Cancer-Associated Thrombosis
February 3rd 2023Craig Coleman, PharmD, Professor at the University of Connecticut, and the Observational Study in Cancer-Associated Thrombosis for Rivaroxaban (OSCAR) study's principal investigator discusses the ins and outs of the study.